Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 10
2003 4
2004 5
2005 4
2006 6
2007 11
2008 8
2009 9
2010 9
2011 15
2012 7
2013 13
2014 9
2015 8
2016 11
2017 9
2018 7
2019 5
2020 4
2021 6
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, Sahin K, Bauersachs R; SURPRISE investigators. Beyer-Westendorf J, et al. Lancet Haematol. 2017 Mar;4(3):e105-e113. doi: 10.1016/S2352-3026(17)30014-5. Epub 2017 Feb 16. Lancet Haematol. 2017. PMID: 28219692 Clinical Trial.
Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared with fondaparinux because it does not require daily subcutaneous injection and is cheaper. We compared efficacy outcomes in patients with superficial-vein thrombosis and additional risk factors giv …
Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compared with fondaparinux because it does not require daily subcu …
Fondaparinux-associated heparin-induced thrombocytopenia.
Bhatt VR, Aryal MR, Shrestha R, Armitage JO. Bhatt VR, et al. Eur J Haematol. 2013 Nov;91(5):437-41. doi: 10.1111/ejh.12179. Epub 2013 Aug 20. Eur J Haematol. 2013. PMID: 23905719
Fondaparinux is in fact recommended as an option for the management of HIT. ...RESULTS: A total of eight cases of fondaparinux-associated HIT were identified. Fondaparinux-associated HIT occurred in the setting of pro-inflammatory state, prior HIT, or exposur
Fondaparinux is in fact recommended as an option for the management of HIT. ...RESULTS: A total of eight cases of fondaparinux
Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, Drescher M, Jayaram N, Holmes C, Feldman L, Zattra O, Farrar-Muir H, Cronin C, Basch E, Weiss A, Connors JM; CANVAS Investigators. Schrag D, et al. JAMA. 2023 Jun 13;329(22):1924-1933. doi: 10.1001/jama.2023.7843. JAMA. 2023. PMID: 37266947 Free PMC article. Clinical Trial.
Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses. MAIN OUTCOMES AND MEASURES: The primary outcome was the recurrent VTE rate at 6 months. ...
Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses. MAIN OUTCOMES AND MEASURE …
Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
Bundhun PK, Shaik M, Yuan J. Bundhun PK, et al. BMC Cardiovasc Disord. 2017 May 8;17(1):116. doi: 10.1186/s12872-017-0552-z. BMC Cardiovasc Disord. 2017. PMID: 28482804 Free PMC article. Review.
BACKGROUND: Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS). ...Even during a follow up period of 30 days or a midterm follow up, major and minor bleeding still signif …
BACKGROUND: Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients wi …
Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: A meta-analysis.
Mu F, Wang M, Huang J, Wang F. Mu F, et al. Eur J Obstet Gynecol Reprod Biol. 2023 Aug;287:29-35. doi: 10.1016/j.ejogrb.2023.05.031. Epub 2023 May 27. Eur J Obstet Gynecol Reprod Biol. 2023. PMID: 37276726 Free article. Review.
OBJECTIVE: Current opinion on the superiority of fondaparinux versus low molecular-weight heparin (LMWH) in treating recurrent miscarriage is controversial. This meta-analysis aimed to comprehensively compare the pregnancy outcomes and adverse events in patients with recur …
OBJECTIVE: Current opinion on the superiority of fondaparinux versus low molecular-weight heparin (LMWH) in treating recurrent miscar …
Efficacy and safety of fondaparinux in patients with acute coronary syndromes.
Bassand JP, Richard-Lordereau I, Cadroy Y. Bassand JP, et al. Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1013-26. doi: 10.1586/14779072.5.6.1013. Expert Rev Cardiovasc Ther. 2007. PMID: 18035917 Review.
Fondaparinux (Arixtra, GlaxoSmithKline) is a synthetic, selective, activated Factor X inhibitor. ...Fondaparinux was compared with enoxaparin or usual care, depending on the setting. ...
Fondaparinux (Arixtra, GlaxoSmithKline) is a synthetic, selective, activated Factor X inhibitor. ...Fondaparinux was compared
Treatment for superficial thrombophlebitis of the leg.
Di Nisio M, Wichers IM, Middeldorp S. Di Nisio M, et al. Cochrane Database Syst Rev. 2018 Feb 25;2(2):CD004982. doi: 10.1002/14651858.CD004982.pub6. Cochrane Database Syst Rev. 2018. PMID: 29478266 Free PMC article. Review.
Major bleeding was infrequent in both groups with very wide CIs around risk estimate (RR 0.99, 95% CI 0.06 to 15.86; moderate-quality evidence). In one RCT on 472 high-risk participants with ST, fondaparinux was associated with a non-significant reduction of symptomatic VT …
Major bleeding was infrequent in both groups with very wide CIs around risk estimate (RR 0.99, 95% CI 0.06 to 15.86; moderate-quality eviden …
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Tsiridis E, Gamie Z, George MJ, Hamilton-Baille D, West RM, Giannoudis PV. Tsiridis E, et al. Curr Vasc Pharmacol. 2011 Jan;9(1):42-7. doi: 10.2174/157016111793744670. Curr Vasc Pharmacol. 2011. PMID: 21044026 Review.
The safety and efficacy of fondaparinux was evaluated in a new protocol used for DVT prophylaxis. ...The most current large randomised controlled studies investigating the administration of fondaparinux following joint arthroplasty or hip fracture surgery, have demo …
The safety and efficacy of fondaparinux was evaluated in a new protocol used for DVT prophylaxis. ...The most current large randomise …
Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia.
Nilius H, Kaufmann J, Cuker A, Nagler M. Nilius H, et al. Am J Hematol. 2021 Jul 1;96(7):805-815. doi: 10.1002/ajh.26194. Epub 2021 May 3. Am J Hematol. 2021. PMID: 33857342 Free PMC article.
The pooled rates of platelet recovery ranged from 74% (bivalirudin) to 99% (fondaparinux), TE from 1% (fondaparinux) to 7% (danaparoid), major bleeding from 1% (DOAC) to 14% (bivalirudin), and death from 7% (fondaparinux) to 19% (bivalirudin). ...DISCUSSION: …
The pooled rates of platelet recovery ranged from 74% (bivalirudin) to 99% (fondaparinux), TE from 1% (fondaparinux) to 7% (da …
Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis.
Kumar A, Talwar A, Farley JF, Muzumdar J, Schommer JC, Balkrishnan R, Wu W. Kumar A, et al. J Am Heart Assoc. 2019 May 21;8(10):e012184. doi: 10.1161/JAHA.119.012184. J Am Heart Assoc. 2019. PMID: 31070069 Free PMC article.
However, the odds of major bleeding in the fondaparinux group were 1.48 times the odds in the LMWH group ( OR =1.48 [1.15-1.90]). Conclusions Fondaparinux was associated with a superior efficacy in terms of reduction of venous thromboembolism in this meta-analysis. …
However, the odds of major bleeding in the fondaparinux group were 1.48 times the odds in the LMWH group ( OR =1.48 [1.15-1.90]). Con …
154 results